AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31831072
Drug: Prediction model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction model for daily evolution of disease severity
Trial: 31832624
Drug: Immunoadsorption (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoadsorption (IA) - 2.0-fold individual total plasma volume on day 1, 2.5-fold on days 2-5, 5 treatments over 5 consecutive days.
Trial: 31832624
Drug: Plasma Exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma Exchange (PE) - 2 liters of plasma removed each day, substituted by 5% human albumin solution, 5 treatments over 5 consecutive days.
Trial: 31833010
Drug: V-Go insulin
RxNorm normalized name: Go-dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V-Go insulin delivery device
Trial: 31835236
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (G) 1000 mg/m² combined with Pazopanib (P) for a median of 3.8 months
Trial: 31835495
Drug: BAY 1125976
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY 1125976 (allosteric AKT inhibitor)
Trial: 31836928
Drug: Ceftazidime-avibactam (2000/500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime-avibactam (2000/500 mg by 2-h intravenous infusion every 8 h, adjusted for renal function)
Trial: 31836927
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg twice-daily oral administration of cimetidine
Trial: 31836927
Drug: lucerastat administered
RxNorm normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lucerastat administered alone
Trial: 31839594
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D deficiency (< 10 ng/mL)
Trial: 31839594
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D low level (10-29.9 ng/mL)
Trial: 31839594
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D normal level (≥ 30 ng/mL)
Trial: 31839997
Drug: Pandemic influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic influenza virus vaccine (AS03-adjuvanted)
Trial: 31839997
Drug: Pandemic influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic influenza virus vaccine (A/H9N2)
Trial: 31839997
Drug: Chimeric HA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric HA stalk-based universal influenza virus vaccine
Trial: 31843865
Drug: Oral meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral meloxicam (preclinical only)
Trial: 31844684
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction followed by IVF treatment
Trial: 31844684
Drug: IVF treatment-only
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment-only
Trial: 31845423
Drug: Higher L/A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher L/A ratios in children with overweight/obesity compared to normal weight children
Trial: 31845423
Drug: Upper quartile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper quartile L/A ratio in girls with overweight/obesity
Trial: 31845423
Drug: Upper quartile
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper quartile L/A ratio in boys with overweight/obesity
Trial: 31847861
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) treatment during adjuvant chemotherapy
Trial: 31848762
Drug: Submerged two-stage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submerged two-stage implants
Trial: 31848762
Drug: Nonsubmerged one-stage
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsubmerged one-stage implants
Trial: 31848820
Drug: Preoperative high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative high protein β-hydroxy-β-methyl butyrate oral nutritional support (ONS)
Trial: 31848820
Drug: Postoperative nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative nutritional support targeting at least 1 g/kg/day protein and 20 kcal/kg/day caloric intake
Trial: 31849202
Drug: Ra-223 (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ra-223 (55 kBq/kg intravenously every 4 weeks) up to 6 cycles with endocrine therapy
Trial: 31849542
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg/week plus MTX (ETN+MTX)
Trial: 31850192
Drug: Nivolumab (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (exact dosage and duration not specified)
Trial: 31850360
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g milk protein concentrate, 25 g maltodextrin, 7.75 g canola oil (treatment group)
Trial: 31850853
Drug: Resident-run oral
RxNorm normalized name: Prevident Oral Paste Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resident-run oral health campaigns
Trial: 31851518
Drug: DNA-PKcs inhibitors
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA-PKcs inhibitors with good PI3 kinase selectivity
Trial: 31851762
Drug: Busulfan dosing
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan dosing based on fat free mass (FFM)
Trial: 31851762
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing based on total body mass
Trial: 31852810
Drug: TLC388 (Lipotecan)
RxNorm normalized name: Lipotecan
DrugBank: Lipotecan (DB17385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC388 (Lipotecan) Hydrochloride, 40 mg/m², administered for a median of 2 treatment cycles (range, 0-6)
Trial: 31852847
Drug: Intermittent prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent prednisone administration
Trial: 31852847
Drug: Chronic daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic daily steroid use
Trial: 31853198
Drug: CC-115 10
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-115 10 mg BID
Trial: 31853198
Drug: CC-115 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-115 (various doses 0.5-40 mg/day)
Trial: 31853198
Drug: CC-115 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-115 (10 mg BID)
Trial: 31853198
Drug: CC-115 (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-115 (in bioavailability substudy)
Trial: 31853198
Drug: CC-115 (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-115 (in cohort expansion)
Trial: 31853198
Drug: CC-115 (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-115 (in chronic lymphocytic leukemia/small lymphocytic lymphoma)
Trial: 31853265
Drug: Capmatinib 300
RxNorm normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capmatinib 300 mg BID
Trial: 31857311
Drug: Antibiotic prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prescription (yes/no)
Trial: 31857311
Drug: Antibiotic requests
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic requests
Trial: 31858327
Drug: Dacomitinib 45
RxNorm normalized name: dacomitinib 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib 45 mg every 12 hours for six doses in a 7-day lead-in cycle (cycle 0) followed by 60 mg every 12 hours for six doses in a 14-day cycle (cycle 1)
Trial: 31859468
Drug: Polypodium leucotomos
RxNorm normalized name: Polypodium leucotomos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypodium leucotomos extract (PLE) 480 mg daily for 28 days
Trial: 31860140
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (BV) 1.8 mg/kg with MEC (mitoxantrone, etoposide, cytarabine)
Trial: 31861009
Drug: Omadacycline (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omadacycline (oral form)
Trial: 31863283
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg starting dose
Trial: 31863283
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg starting dose in Del19-positive patients
Trial: 31863283
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg starting dose in Asian patients
Trial: 31863305
Drug: CYP2D6-specific drugs
RxNorm normalized name: PACIFIC OYSTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP2D6-specific drugs
Trial: 31865734
Drug: Hydrogen-oxygen therapy
RxNorm normalized name: carbon dioxide / helium / hydrogen / nitrogen / oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-oxygen therapy for 0.5, 1, and 2 months
Trial: 31866281
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg orally twice per day in 28-day cycles until disease progression or unacceptable toxicity
Trial: 31866516
Drug: Levonorgestrel 52-mg
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel 52-mg intrauterine system
Trial: 31868997
Drug: Androgen-deprivation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen-deprivation therapy (32%)
Trial: 31869400
Drug: Anthracycline treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline treatment (86% epirubicin, 7% doxorubicin)
Trial: 31869413
Drug: Allogeneic hematopoietic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) with donor lymphocyte infusions (DLI) for mixed chimerism or residual or relapsed disease.
Trial: 31869417
Drug: NK cells
RxNorm normalized name: NK Cells
DrugBank: Natural Killer Cell (DB15721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NK cells expressing 3 inhibitory receptors (KIR2DL1/2DL3/3DL1)
Trial: 31872928
Drug: Single-agent pazopanib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent pazopanib at a dose of 800 mg daily
Trial: 31875196
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg/d for 14 weeks
Trial: 31875931
Drug: Dotinurad 2
RxNorm normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dotinurad 2 mg/day
Trial: 31875931
Drug: Dotinurad 4
RxNorm normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dotinurad 4 mg/day
Trial: 31876107
Drug: Sirolimus combined
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus combined with oral metronomic therapy (twice daily celecoxib, alternating etoposide and cyclophosphamide every three weeks)
Trial: 31876911
Drug: Acalabrutinib 100
RxNorm normalized name: acalabrutinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib 100 mg twice daily for a median of 41 months (range 0.2-58 months)
Trial: 31876927
Drug: Coronary sinus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coronary sinus neuropeptide Y (CS NPY) levels ≥ 130 pg/mL
Trial: 31879842
Drug: Lanreotide autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel 120 mg/28 days
Trial: 31881608
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices
Trial: 31881853
Drug: Trametinib (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (daily oral at full dose for 18 cycles of 28 days)
Trial: 31884564
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR 6 µg
Trial: 31884564
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR 10 µg
Trial: 31884564
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR 15 µg
Trial: 31884564
Drug: Bimatoprost SR
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost SR 20 µg
Trial: 31884564
Drug: Topical bimatoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical bimatoprost 0.03% (Control)
Trial: 31884564
Drug: Overall study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall study eyes (all doses combined)
Trial: 31884676
Drug: GSK's IIV4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK's IIV4 (one dose)
Trial: 31884676
Drug: GSK's IIV4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK's IIV4 (second dose)
Trial: 31885349
Drug: Chemotherapy (N-chemo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (N-chemo group)
Trial: 31885750
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg mepolizumab (subcutaneous)
Trial: 31887431
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg qd)
Trial: 31888588
Drug: Visit purpose
RxNorm normalized name: Corona Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visit purpose (dental examination or treatment with conscious sedation)
Trial: 31889230
Drug: Dotinurad 1
RxNorm normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dotinurad 1 mg (single oral administration)
Trial: 31889307
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), 12-16 sessions
Trial: 31890041
Drug: EVO 2.5
RxNorm normalized name: Therapevo 2.5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVO 2.5 mg
Trial: 31890041
Drug: EVO 5
RxNorm normalized name: Stalevo 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVO 5 mg
Trial: 31890041
Drug: EVO 10
RxNorm normalized name: Stalevo 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVO 10 mg
Trial: 31890041
Drug: SITA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SITA 100 mg
Trial: 31890043
Drug: 12-months exercise
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-months exercise program (a combination of aerobic and strength training for a minimum of 150 min per week)
Trial: 31890266
Drug: 12-week physical
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week physical activity intervention (4 weekly aerobic and strength training sessions)
Trial: 31890902
Drug: V7 TB
RxNorm normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V7 TB vaccine (10 µg of hydrolyzed heat-killed mycobacteria)
Trial: 31890996
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (LLT) including statin and/or ezetimibe
Trial: 31893514
Drug: AAV5-hFVIII-SQ gene
RxNorm normalized name: AAV5-hFIXco-Padua
DrugBank: Etranacogene dezaparvovec (DB16791)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV5-hFVIII-SQ gene therapy
Trial: 31894377
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) treatment in treatment-naïve patients
Trial: 31894377
Drug: Intravitreal aflibercept
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal aflibercept (IVT-AFL) treatment in previously treated patients
Trial: 31894704
Drug: Metronomic oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic oral vinorelbine in combination with immune-checkpoint inhibitors
Trial: 31895611
Drug: AMG 420
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 420 at 400 μg/d (maximum tolerated dose)
Trial: 31895611
Drug: AMG 420
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 420 at 0.2-800 μg/d
Trial: 31895611
Drug: AMG 420
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 420 at 800 μg/d
Trial: 31895611
Drug: AMG 420
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 420 at 400 μg/d
Trial: 31896519
Drug: Lurbinectedin monotherapy
RxNorm normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lurbinectedin monotherapy (Stratum C)
Trial: 31897676
Drug: Etoposide, methylprednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) combination chemotherapy
Trial: 31898493
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) at a low dose of 75μg/d for 1 month, adjusted to 150μg/d if lesions did not improve, for a total treatment duration of 6 months.
Trial: 31899729
Drug: Cholic acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cholic acid (10-15 mg·kg·day)
Trial: 31899873
Drug: BBBD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBBD with MR-guided focused ultrasound (MRgFUS) during adjuvant TMZ chemotherapy
Trial: 31900121
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg i.v. every 2 weeks for 4 cycles preoperatively with concomitant radiation therapy of bladder and pelvic region (max. 50.4 Gy)
Trial: 31903182
Drug: R-CHOP plus
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP plus B-cell receptor/NF-κB-double-targeting
Trial: 31905377
Drug: hs-cTnI cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnI cutoff of 2.5 ng/L
Trial: 31905377
Drug: hs-cTnT concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnT concentrations less than 5 ng/L
Trial: 31905377
Drug: hs-cTnI concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-cTnI concentrations less than 2 ng/L
Trial: 31907183
Drug: High-Dose Chloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Chloroquine
Trial: 31907183
Drug: Standard-Dose Chloroquine
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-Dose Chloroquine
Trial: 31907538
Drug: BMD correlation
RxNorm normalized name: BACITRACIN METHYLENEDISALICYLATE 50 g in 0.45 kg ORAL GRANULE [BMD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMD correlation with parathyroid hormone, FGF23, thyrotropin, and glycated hemoglobin (HbA1c) levels
Trial: 31907737
Drug: Matched treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched treatment based on molecular targets
Trial: 31908441
Drug: Bronchodilator Responsiveness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchodilator Responsiveness (BDR)
Trial: 31908444
Drug: Daily variability
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily variability in chest tightness and wheezing
Trial: 31908520
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine combined with 2 μg/kg dexmedetomidine (LD group)
Trial: 31908520
Drug: 0.1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% ropivacaine (L group)
Trial: 31909303
Drug: Tadalafil and
RxNorm normalized name: finasteride and tadalafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil and subcutaneous BNP
Trial: 31910916
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy for Cognitively Impaired Older Adults (ST-CI)
Trial: 31912493
Drug: Adjunctive perampanel
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjunctive perampanel (mean daily dose 7.0 mg/day)
Trial: 31912905
Drug: Neratinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib plus HDAC inhibitors
Trial: 31915166
Drug: Intra-arterial thrombectomy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial thrombectomy (IAT) with intravenous thrombolysis (IVT) at the nearest primary stroke centre (PSC)
Trial: 31915192
Drug: Gentamicin exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin exposure (6 mg/kg)